Biogen Inc. diskutieren
Biogen Inc.
WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /
144,70 €
-3,21 %
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Royal Bank of Canada from $282.00 to $292.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $302.00 price target on the stock, down previously from $340.00.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $277.00 to $251.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $285.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $285.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $292.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $292.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $285.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Royal Bank of Canada from $292.00 to $269.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at BMO Capital Markets from $260.00 to $230.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $270.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $300.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at TD Cowen from $300.00 to $275.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $270.00 to $255.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Truist Financial Co. from $302.00 to $220.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Truist Financial Co. from $220.00 to $210.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $300.00 to $241.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Neueste Beiträge
HC_Wainwright in Discuss Nektar Therapeutics